Description
On the eve of the rare disease day, our guests discuss the compelling reasons why AATD stands out as the prime candidate for gene therapy. This talk addresses the pertinence of the subject in the current research landscape and highlight ongoing global trials opening the door for new opportunities in this field.
Faculty
- Aleksander Krag (Moderator)
- Aftab Ala (Faculty)
- Pavel Strnad (Faculty)
- Alice Turner (Faculty)
Related episodes
- EASL Studio from EASL Congress 2023: Clinical trials in rare diseases – opportunities and challenges
- EASL Studio from ILC 2022: Rare Liver Diseases – A growing landscape of opportunities and challenges
This episode is scheduled in honour of the Rare Disease Day (29 February).
ℹ️ Please click here to access the podcast version of this EASL Studio episode.